Neuroprotection by the Selective Cyclooxygenase-2 Inhibitor SC-236 Results in Improvements in Behavioral Deficits
Induced by Reversible Spinal Cord Ischemia I schemia activates a cascade that leads to the induction and expression of genes in a variety of cell types throughout the central nervous system (CNS). [1] [2] [3] [4] [5] [6] [7] Because it is associated with the production of both cytokines and immediate early genes that may be detrimental to CNS cells, 8 the inflammatory mediator pathway has been implicated as a potential contributor to ischemia-induced deficits. The product of one such immediate early gene, cyclooxygenase-2 (COX-2) (an inducible form of COX), has become the focus of attention because it is the rate-limiting enzyme involved in arachidonic acid metabolism, thereby generating prostaglandins and thromboxanes, molecules that play important roles in supporting and sustaining the inflammatory response. 9 COX-2 can be induced in neurons and in cells associated with the cerebral vasculature after various CNS insults, including global ischemia. 10 -13 Since COX-2 immunoreactivity also has been detected in the human brain after cerebral ischemia, it has been proposed that COX-2 and its reaction products participate in ischemic injury in the human brain. 14 In view of these findings, the possibility that COX-2 may be a crucial component in ischemia-induced neurodegeneration has been the subject of several recent studies that used rodent models of focal ischemia. The COX-2 inhibitors SC-58125 and NS-398 have been shown to prevent delayed death of hippocampal neurons 15 and to reduce infarct size 16 after global ischemia, respectively. In contrast, Hara et al 17 reported that total infarct volume was unaffected by NS-398. Nevertheless, prostaglandin levels in the peri-ischemic region were decreased in response to NS-398 treatment, prompting the authors to conclude that COX-2 inhibition may be important in peri-ischemic pathophysiology. 17 However, to our knowledge, administration of a COX-2 inhibitor has not been shown to improve behavioral function(s) after transient spinal cord ischemia.
In consideration of the potential for COX-2 as a target for pharmacological intervention, the main purpose of the present study was to determine whether administration of a COX-2 inhibitor attenuates the behavioral deficits consequent to an ischemic insult in an established, validated animal model (the reversible rabbit spinal cord ischemia model), using a welldefined clinical rating scale. 18, 19 The selective COX-2 inhibitor 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzene-sulfonamide (SC-236) was chosen on the basis of its selectivity (high COX-2/COX-1 ratio of 1780/1), high potency (in vitro inhibition in the nanomolar range), and long plasma half-life (117 hours with a dose of 20 mg/kg in rodents). 20 
Materials and Methods
Spinal cord ischemia was produced in the rabbit spinal cord ischemia model by occluding the aorta for up to 40 minutes, as described previously. 18, 19, 21 Briefly, the aorta of male New Zealand White rabbits weighing 3 to 3.5 kg was exposed at the level of the renal arteries through a midline abdominal incision, and a small-diameter Tygon tube was used to form a snare around the aorta just distal to the left (caudal) renal artery. The ends of this tube were threaded through a small plastic button followed by a larger-diameter tube, and the incision was closed around the tubing so that the free ends were accessible externally. Rabbits were allowed to recover from anesthesia for at least 2 hours, at which time it is possible to establish whether sensations and motor activity are normal. Pulling on and clamping the protruding small tubing occludes the aorta a predetermined period, and release restores blood flow, after which all tubing is removed and the small hole in the abdominal wall is closed with surgical clips. The duration of ischemia was selected to span all grades of damage, ranging from full recovery to permanent paraplegia. Zivin et al 21 showed previously that there was a good correlation between the length of occlusion and the extent of spinal cord damage. Whereas short periods of occlusion (Ͻ15 minutes) produced no apparent neurological deficits, intermediate (15 to 30 minutes) and long (Ͼ30 minutes) occlusion times caused partial neurological deficits involving gray matter, while sparing long white matter tracts, gray horns, dorsal root ganglia, and paraplegia with extensive lesions throughout the gray matter from the upper lumbar region to the end of the sacral segments.
Animals were observed while the aorta was occluded and for 1 hour after the snare was released, followed by daily examinations for the next 48 hours. The extent of neurological function at 18 hours was graded on a binary scoring system of functional or paraplegic. Rabbits were judged to be functional if they ambulated normally, responded normally to noxious stimuli, and had normal bowel and bladder function. This group also included abnormal animals that did not hop normally, were less responsive than normal to pinching of the hind limbs, and exhibited variable bowel and bladder function. Animals showing any degree of motor impairment (from barely detectable to severe) were included in this grade and were considered to be functional for quantal analysis. Rabbits were assessed as paraplegic if they were completely unresponsive to noxious stimuli in the hindquarters and were incontinent. The graders were blinded at all times as to the treatments the animals received.
SC-236 was administered at a dose of 10 to 100 mg/kg SC, 5 minutes after initiation of aortic occlusion. Two groups of vehicleinjected (1 mL/kg) control animals, one given dimethyl sulfoxide (DMSO), the vehicle required to solubilize SC-236, and the other normal saline, also were included in the study. After 48 hours, The duration of occlusion for individual animals was predetermined to be from 10 to 40 minutes, providing a wide range of ischemia for each experimental (drug-or vehicle-treated) group. The group ET 50 , representing the duration of ischemia (minutes) associated with a 50% probability of resultant permanent paraplegia, 21 was statistically analyzed and graphically demonstrated by using computer construction of an ischemic duration quantal "dose-response" curve for each group that is similar to the LD 50 curves of pharmacological studies. 22 Statistical significance was assessed with the group t test and adjusted for multiple comparisons with the Bonferroni correction (PϾ0.05). 23 Neuroprotection was demonstrated if a drug significantly prolonged the ET 50 compared with the corresponding control (vehicle-treated) group.
Percentage of rabbits that are paraplegic as a function of the duration of ischemia (aortic occlusion) in minutes measured 18 hours after spinal cord ischemia. The curve labeled DMSOtreated (solid line) shows the development of paraplegia in DMSO-treated rabbits. The curve labeled COX-2 inhibitor (large dashed line) shows that SC-236 (100 mg/kg SC) increases the tolerance of aortic occlusion by approximately 11.3 minutes. The horizontal bars represent standard errors at the ET 50 required to produce paraplegia. 
Results
Since SC-236 is relatively insoluble in aqueous solution, a quantal analysis curve for DMSO, the vehicle required to solubilize SC-236, was compared with a quantal analysis curve for normal saline (0.9% saline), the more commonly used vehicle in the rabbit spinal cord ischemia model. The comparison was made to determine whether DMSO itself affects the behavioral response. When behavioral analysis was assessed 18 hours after aortic occlusion, the ET 50 of the DMSO-treated group (18.84Ϯ3.19 minutes) was not significantly different from that of the saline-treated group (22.97Ϯ1.87 minutes). By 48 hours after occlusion, the ET 50 for the DMSO-treated group had increased slightly to 20.24Ϯ2.09 minutes, whereas that for the saline group remained unchanged (Table 1) . Nonetheless, no significant statistical differences (PϾ0.05) in the ET 50 values for the different vehicle-treated groups were noted at either time point. SC-236 treatment (100 mg/kg) significantly prolonged the ET 50 of the group to 30.04Ϯ3.55 minutes (PϽ0.01) at 18 hours after occlusion, a shift of approximately 59% compared with the DMSO group, whereas effects of the lower doses were less pronounced ( Figure; Tables 1 and 2 ). In addition, the effect of the higher dose (100 mg/kg) of SC-236 was durable since there was still a significant difference (PϽ0.05) in the ET 50 between the DMSO-treated (20.24Ϯ2.09 minutes) and drug-treated (30.04Ϯ3.55 minutes) groups by 48 hours after the initial occlusion (Tables 1 and 3) .
To determine whether the neuroprotective effects of SC-236 could be attributed to the induction of hypothermia or hyperthermia, we determined whether the dose of SC-236 (ie, 100 mg/kg) that was found to be neuroprotective alters body temperature. Five rabbits were injected with SC-236 (100 mg/kg SC) after a baseline body temperature was established with the use of a digital rectal thermometer. Baseline temperature was 102.7Ϯ0.3°F. At 1, 2, and 18 hours after SC-236 
Results are behavioral readings for each group of rabbits and are the number of rabbits either functional (F) or paraplegic (P) for each treatment group. Rabbits were treated subcutaneously with either saline (nϭ9), DMSO (nϭ14), SC-236 (10 mg/kg; nϭ14), SC-236 (50 mg/kg; nϭ12), or SC-236 (100 mg/kg; nϭ13) administered 5 minutes after the start of occlusion. Ellipses indicate that an animal was not tested for that specific group or duration of ischemia. administration, body temperature was 102.8Ϯ0.3°F, 102.8Ϯ0.5°F, and 103.0Ϯ0.3°F, respectively.
Discussion
Recent evidence has provided some insight into the role of inflammatory mediators after an ischemic event. 4,24 -26 Current hypotheses have proposed that the inflammatory reaction is initiated at the level of the microvasculature and within various cell types. 27 For instance, COX-2 mRNA and protein levels have been shown to be significantly increased within neurons and vascular cells after cerebral ischemia and other insults that result in neurodegeneration. 12,28 -32 Moreover, COX-2 protein appears to be expressed not only within ischemic cells but also in cells located in the "penumbra" and in normal cells around the infarct zone. 12 A role for COX-2 in the pathophysiology of the peri-ischemic zone as the infarct enlarges in the later stages of ischemic injury 12 is supported further by the observation that administration of a COX-2 inhibitor reduces ischemia-induced delayed neuronal damage. 15 Although this mechanism requires further investigation, it has been suggested that COX-2 activity is driven by inducible NO synthase production of NO, which in turn supports the production of COX-2 products. 16, 29 Consistent with this, Nogawa et al 29 showed that COX-2 mRNA expression in the brain peaked 12 hours after middle cerebral artery occlusion, at a time when inducible NO synthase also reached peak expression.
In the present study SC-236 served as a pharmacological tool to determine whether COX-2 is involved in the ischemic cascade and resulting behavioral deficits after aortic occlusion in the rabbit spinal cord ischemia model. The results of our study identified inhibition of COX-2 as an effective means to generate a neuroprotective effect (improved behavior) after the onset of spinal cord ischemia, supporting earlier findings that implicated COX-2 involvement in the progression of the ischemic cascade in cerebral ischemia. 12, 15 Furthermore, our results are in agreement with the study of Resnick et al, 33 who showed that the selective COX-2 
Results are behavioral readings for each group of rabbits and are the number of rabbits either functional (F) or paraplegic (P) for each treatment group. Rabbits were treated subcutaneously with either saline (nϭ9), DMSO (nϭ14), SC-236 (10 mg/kg; nϭ14), SC-236 (50 mg/kg; nϭ12), or SC-236 (100 mg/kg; nϭ13) administered 5 minutes after the start of occlusion. Ellipses indicate that an animal was not tested for that particular group or duration of ischemia.
inhibitor SC58125 improved functional outcome after experimental spinal cord injury induced by a different method.
The mechanism responsible for COX-2-mediated neurodegeneration or COX-2 inhibitor neuroprotection in the rabbit spinal cord ischemia model is not clearly understood. In the present study relatively high doses of SC-236 were required to a statistically significant increase in ET 50 values. Since there is no information available on the pharmacokinetics of SC-236 in rabbits, it is possible that high doses of SC-236 were required because of poor penetration of SC-236 into the CNS, the spinal cord in particular. Although COX-2 production of prostaglandin, particularly prostaglandin E 2 , which regulates many physiological processes including vasomotility, platelet aggregation, and immunomodulation, 34 has been proposed to perpetuate the ischemic cascade, 12 administration of COX-2 inhibitors after an acute noxious stimulus did not appear to alter prostaglandin synthesis in the rat spinal cord. 35 Thus, further studies are required to understand COX-2 inhibitor effects in the spinal cord after ischemia and to determine whether the neurodegenerative effects of COX-2 are mediated through the synthesis of prostaglandin E 2 or other mediators. The present study focused on the behavioral effects of COX-2 inhibition after ischemia. Since SC-236 was found to be neuroprotective in the rabbit spinal cord ischemia model, histological and neuroanatomical studies are required to determine which neuronal populations of spinal cord neurons mediate the neuroprotective effects of COX-2 inhibitors. Additionally, since COX-2 inhibitors may alter a variety of physiological responses, 9 detailed studies aimed at identifying physiological parameters affected by SC-236 should be conducted in the future. However, in the present study we found that SC-236 did not alter body temperature, suggesting that the neuroprotective effects of SC-236 are not related to the induction of hypothermia or hyperthermia.
Conclusion
We have demonstrated that the selective COX-2 inhibitor SC-236 is neuroprotective in a reversible spinal cord ischemia model using clinical rating scores as the primary end point. COX-2 inhibitors have been used clinically for various indications and have been shown to be safe, effective, and easily administered for the treatment of a variety of diseases. 36 -38 Our results suggest that selective COX-2 inhibitors also may be of therapeutic benefit in the treatment of spinal cord and cerebral ischemia.
